HHS permits compounding of six experimental peptides despite FDA scientists' safety concerns

HHS issued a temporary policy that lets licensed pharmacies and physicians compound six experimental peptides without risk of federal enforcement.

The list includes the injury-recovery duo BPC-157 and TB-500, which have attracted attention from the peptide community.

FDA career scientists warned that there is little evidence these substances are safe or effective.

The move reflects the administration’s push to support the growing peptide market despite scientific objections.